For the sake of flogging dead horses this article by Bioshares is a MUST READ for all.
Thank you for posting. This is an excellent appraise' of the existing and ongoing Vaxinia Trial, highlighting not only the way the virus works, but the future plans of the trial supervisors, that being to enrol and treat bile duct cancer patients, an indication with little or no life expectancy.
The key point to be made here is that we as investors, the trial supervisors and indeed the Vaxinia Founder Professor Yuman Fong, are yet to realise the results of Vaxinia, when treated in humans at Parts 8,9 and perhaps 10 parts to the 10. Collectively we are excited by what we have seen at exceptionally low doses, including disease stabilisation, complete and partial responses. But at dosage rates now 300 times higher than the initial cohorts, one can only imagine the results. Its not like going from unleaded 91 to 95 or even premium 98 fuel. It's like going from unleaded 91 to cryogenically cooled RP-1 (highly refined kerosene) with liquid oxygen, the fuel used by space rockets. One can only wonder at what results we shall see in the new year when Vaxinia is dosed at 300 times the earlier doses administered to Cohorts 1 and 2.
With all due respect I believe some investors are oblivious to what's in play here. Professor Fong is on the cusp of greatness. He has killed all cancers against the NCI 60 pre-clinically. One surmises the only reason this has not been achieved yet in humans is due to the strict impositions (i.e., low dose rates) imposed on him by the FDA, to ensure there was no toxicity when dosing the initial cohorts. Now the Vaxinia dose rates are ramping 100, 300, perhaps 1,000 times the initial dose rates the virus can truly take hold infect and destroy solid tumours, activate the immune system and present parts of the destroyed tumour cells to prime the immune system, as noted by Dr Woodard.
Let's forget about the share price, company management, the broader biotech and macroeconomic space for a few minutes and marvel at what is in play here. We have a world leading scientist, surgeon and esteemed cancer researcher who has stated that, in conjunction with other therapies, vaccines and treatment arms (i.e., OnCARlytics), one day Vaxinia is set to become human therapy, replacing and improving the standard of care, chemotherapy and monoclonal antibodies. Less side effects, stimulated immune systems, eradication of solid tumours within any cancer indication, complete with a viral memory to recognise and destroy the deadly cancer virus when it rear's its ugly again head down the track, as it so often does. Let us contemplate what results could be achieved in patients dosed at 100, 300 if not 1,000 times higher dose rates of Vaxinia than those presented thus far. The results to date have been remarkable to say the least, but what lies ahead?
If at higher dosage rates Vaxinia is successful in performing the tasks outlined by Dr Woodard in the aforementioned article, one cannot place a value on that. It could well do so, given the increased levels of the virus present in late stage patients from the moment they are dosed up with Vaxinia. At present the article notes 98% of all patients with bile duct cancer that has metastasised fail to live longer than 5 years. In short it is a life sentence for all those diagnosed at present with this horrific illness. I for one am hoping at higher doses we can see not only one, as is currently the situation, but many more patients relieved of such a statistic. We can only pray for a day when the FDA approves Vaxinia for treatment in earlier stage patients before their disease has metastasised. Now wouldn't that be something to see.
DYOR Opinions only
Expand
(20min delay)